Contents
25 November 2015
Vol 7, Issue 315
Vol 7, Issue 315
Contents
Focus
- Is all cancer therapy immunotherapy?
Researchers must renew efforts to decipher how standard chemotherapies enhance the effects of targeted immunotherapeutic agents (Müller et al., this issue).
Perspective
- Unmet needs: Research helps regulators do their jobs
New medical products and the need to apply modern tools for their evaluation has spurred opportunities in regulatory science.
Research Articles
- Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade
An antibody-drug conjugate overcomes resistance to immune checkpoint blockade in HER2-positive breast cancer.
- Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Autologous regulatory T cells can be expanded and are well tolerated in patients with recent-onset type 1 diabetes.
- Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis
Neutrophils generate chrondroprotective AnxA1-containing microvesicles that enter immune cell–impenetrable cartilage.
- Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention
Transcriptomic profiling of primate T cells during acute graft-versus-host disease reveals signaling pathways that when inhibited, ameliorate disease.
Editors' Choice
- Big dipper, little dipper
Individuals with an impaired cerebrovascular system are more likely to show increased brain amyloid deposition, potentially a therapeutic opportunity for treating Alzheimer’s disease.
- All systems go for HIV vaccine development
Systematically mapping diverse antibody effector functions induced by candidate HIV vaccines moves toward pinpointing a protective strategy.
- A Notch in our understanding of vascular disease
Atherosclerosis triggers a decrease in endothelial cell Notch expression, affecting vascular homeostasis and disease susceptibility.
- Above the landscape
The metabolome regulates the epigenetic landscape in human pluripotent stem cells.
About The Cover
ONLINE COVER Shedding Light on Graft-Versus-Host Disease. The Aurora borealis (shown) lights up the night sky. In this issue of Science Translational Medicine, Furlan et al. identify a different type of aurora–aurora kinase A—as a potential therapeutic target for graft-versus-host disease after hematopoietic stem cell transplant. [CREDIT: N. PANDEV/ISTOCKPHOTO]
